Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group

Abstract Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of advanced gastrointestinal stromal tumours (GISTs). Imatinib is approved as first line therapy and sunitinib is used in cases of imatinib resistance or intolerance. Compared with conventional treatments, TKIs are delivere...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2014-07, Vol.91 (1), p.35-46
Main Authors: Sodergren, Samantha C, White, Alice, Efficace, Fabio, Sprangers, Mirjam, Fitzsimmons, Deborah, Bottomley, Andrew, Johnson, Colin D
Format: Article
Language:English
Subjects:
Antineoplastic Agents - adverse effects
Europe
Gastrointestinal Stromal Tumors - drug therapy
Gastrointestinal stromal tumour
Hematology, Oncology and Palliative Medicine
Humans
Imatinib
Protein Kinase Inhibitors - adverse effects
Protein-Tyrosine Kinases - antagonists & inhibitors
Quality of Life
Side effects
Sunitinib
Symptoms
Tyrosine kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of advanced gastrointestinal stromal tumours (GISTs). Imatinib is approved as first line therapy and sunitinib is used in cases of imatinib resistance or intolerance. Compared with conventional treatments, TKIs are delivered over longer periods of time and are more specific in their targets (i.e., molecularly targeted), thus presenting different side effect profiles. We review the safety profiles of imatinib and sunitinib, documenting a total of 95 side effects including patient based as well as medically defined outcomes. Gastrointestinal complaints, particularly diarrhoea and nausea, oedema, fatigue and haematological disorders, notably anaemia, are amongst the most prevalent side effects. While there is overlap between the side effect profiles of imatinib and sunitinib, important differences emerge in the frequencies of oedema, hypertension, thyroid functioning, muscle and joint pains, as well as skin and oral conditions. Awareness of potential side effects is informative to both clinician and patient in terms of treatment decision making and can have important implications for treatment adherence and clinical outcome.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2014.01.002